VERACYTE INC (VCYT) Stock Fundamental Analysis
USA - NASDAQ:VCYT - US92337F1075 - Common Stock
39.35 USD
-0.52 (-1.3%)
39.35 USD
0 (0%)
Overall VCYT gets a fundamental rating of 5 out of 10. We evaluated VCYT against 533 industry peers in the Biotechnology industry. Both the profitability and the financial health of VCYT get a neutral evaluation. Nothing too spectacular is happening here. VCYT is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year VCYT was profitable.
VCYT had a positive operating cash flow in the past year.
In the past 5 years VCYT reported 4 times negative net income.
In multiple years VCYT reported negative operating cash flow during the last 5 years.
1.2 Ratios
With an excellent Return On Assets value of 2.22%, VCYT belongs to the best of the industry, outperforming 89.83% of the companies in the same industry.
VCYT's Return On Equity of 2.41% is amongst the best of the industry. VCYT outperforms 90.77% of its industry peers.
With an excellent Return On Invested Capital value of 2.93%, VCYT belongs to the best of the industry, outperforming 90.21% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.22% | ||
| ROE | 2.41% | ||
| ROIC | 2.93% |
ROA(3y)-2.66%
ROA(5y)-4.4%
ROE(3y)-2.83%
ROE(5y)-4.73%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 6.12%, VCYT belongs to the best of the industry, outperforming 91.34% of the companies in the same industry.
The Operating Margin of VCYT (9.70%) is better than 91.71% of its industry peers.
The Gross Margin of VCYT (68.53%) is better than 80.98% of its industry peers.
In the last couple of years the Gross Margin of VCYT has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.7% | ||
| PM (TTM) | 6.12% | ||
| GM | 68.53% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.39%
GM growth 5Y-0.79%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), VCYT is destroying value.
VCYT has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, VCYT has more shares outstanding
VCYT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
VCYT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | N/A |
ROIC/WACC0.33
WACC8.78%
2.3 Liquidity
VCYT has a Current Ratio of 6.23. This indicates that VCYT is financially healthy and has no problem in meeting its short term obligations.
VCYT has a Current ratio of 6.23. This is in the better half of the industry: VCYT outperforms 66.10% of its industry peers.
A Quick Ratio of 5.94 indicates that VCYT has no problem at all paying its short term obligations.
VCYT has a Quick ratio of 5.94. This is in the better half of the industry: VCYT outperforms 63.47% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.23 | ||
| Quick Ratio | 5.94 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 353.33% over the past year.
Looking at the last year, VCYT shows a quite strong growth in Revenue. The Revenue has grown by 16.41% in the last year.
The Revenue has been growing by 29.93% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)353.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.32%
Revenue 1Y (TTM)16.41%
Revenue growth 3Y26.64%
Revenue growth 5Y29.93%
Sales Q2Q%13.82%
3.2 Future
The Earnings Per Share is expected to grow by 50.66% on average over the next years. This is a very strong growth
Based on estimates for the next years, VCYT will show a quite strong growth in Revenue. The Revenue will grow by 9.91% on average per year.
EPS Next Y33.17%
EPS Next 2Y67.82%
EPS Next 3Y57.77%
EPS Next 5Y50.66%
Revenue Next Year12.89%
Revenue Next 2Y11.38%
Revenue Next 3Y10.9%
Revenue Next 5Y9.91%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 103.55 indicates a quite expensive valuation of VCYT.
Based on the Price/Earnings ratio, VCYT is valued cheaper than 89.83% of the companies in the same industry.
VCYT is valuated expensively when we compare the Price/Earnings ratio to 25.89, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 46.57, which means the current valuation is very expensive for VCYT.
Based on the Price/Forward Earnings ratio, VCYT is valued cheaper than 90.02% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 34.59. VCYT is valued slightly more expensive when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 103.55 | ||
| Fwd PE | 46.57 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, VCYT is valued cheaper than 91.34% of the companies in the same industry.
VCYT's Price/Free Cash Flow ratio is rather cheap when compared to the industry. VCYT is cheaper than 93.79% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 31.52 | ||
| EV/EBITDA | 38.05 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates VCYT does not grow enough to justify the current Price/Earnings ratio.
VCYT has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as VCYT's earnings are expected to grow with 57.77% in the coming years.
PEG (NY)3.12
PEG (5Y)N/A
EPS Next 2Y67.82%
EPS Next 3Y57.77%
5. Dividend
5.1 Amount
VCYT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
39.35
-0.52 (-1.3%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners109.55%
Inst Owner Change2.86%
Ins Owners0.56%
Ins Owner Change-4.94%
Market Cap3.10B
Revenue(TTM)495.14M
Net Income(TTM)30.32M
Analysts83.33
Price Target42.94 (9.12%)
Short Float %8.59%
Short Ratio7.36
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-15.65%
Min EPS beat(2)-110.32%
Max EPS beat(2)79.03%
EPS beat(4)2
Avg EPS beat(4)-1.91%
Min EPS beat(4)-110.32%
Max EPS beat(4)79.03%
EPS beat(8)5
Avg EPS beat(8)108.97%
EPS beat(12)8
Avg EPS beat(12)67.3%
EPS beat(16)12
Avg EPS beat(16)58.01%
Revenue beat(2)2
Avg Revenue beat(2)4.54%
Min Revenue beat(2)3.31%
Max Revenue beat(2)5.76%
Revenue beat(4)3
Avg Revenue beat(4)2.42%
Min Revenue beat(4)-0.39%
Max Revenue beat(4)5.76%
Revenue beat(8)7
Avg Revenue beat(8)4.03%
Revenue beat(12)11
Avg Revenue beat(12)4.6%
Revenue beat(16)15
Avg Revenue beat(16)5.32%
PT rev (1m)2.13%
PT rev (3m)1.69%
EPS NQ rev (1m)5.91%
EPS NQ rev (3m)2.38%
EPS NY rev (1m)5.86%
EPS NY rev (3m)-22.95%
Revenue NQ rev (1m)0.39%
Revenue NQ rev (3m)0.21%
Revenue NY rev (1m)0.04%
Revenue NY rev (3m)1.74%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 103.55 | ||
| Fwd PE | 46.57 | ||
| P/S | 6.25 | ||
| P/FCF | 31.52 | ||
| P/OCF | 28.6 | ||
| P/B | 2.46 | ||
| P/tB | 7.78 | ||
| EV/EBITDA | 38.05 |
EPS(TTM)0.38
EY0.97%
EPS(NY)0.84
Fwd EY2.15%
FCF(TTM)1.25
FCFY3.17%
OCF(TTM)1.38
OCFY3.5%
SpS6.29
BVpS15.99
TBVpS5.06
PEG (NY)3.12
PEG (5Y)N/A
Graham Number11.69
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.22% | ||
| ROE | 2.41% | ||
| ROCE | 3.71% | ||
| ROIC | 2.93% | ||
| ROICexc | 4.08% | ||
| ROICexgc | 54.52% | ||
| OM | 9.7% | ||
| PM (TTM) | 6.12% | ||
| GM | 68.53% | ||
| FCFM | 19.83% |
ROA(3y)-2.66%
ROA(5y)-4.4%
ROE(3y)-2.83%
ROE(5y)-4.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.39%
GM growth 5Y-0.79%
F-Score8
Asset Turnover0.36
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 44.87% | ||
| Cap/Sales | 2.03% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 153.79% | ||
| Profit Quality | 323.94% | ||
| Current Ratio | 6.23 | ||
| Quick Ratio | 5.94 | ||
| Altman-Z | N/A |
F-Score8
WACC8.78%
ROIC/WACC0.33
Cap/Depr(3y)39.24%
Cap/Depr(5y)36.19%
Cap/Sales(3y)2.72%
Cap/Sales(5y)2.61%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)353.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.32%
EPS Next Y33.17%
EPS Next 2Y67.82%
EPS Next 3Y57.77%
EPS Next 5Y50.66%
Revenue 1Y (TTM)16.41%
Revenue growth 3Y26.64%
Revenue growth 5Y29.93%
Sales Q2Q%13.82%
Revenue Next Year12.89%
Revenue Next 2Y11.38%
Revenue Next 3Y10.9%
Revenue Next 5Y9.91%
EBIT growth 1Y426.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year275.46%
EBIT Next 3Y68.01%
EBIT Next 5Y45.61%
FCF growth 1Y237.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y181.75%
OCF growth 3YN/A
OCF growth 5YN/A
VERACYTE INC / VCYT FAQ
What is the fundamental rating for VCYT stock?
ChartMill assigns a fundamental rating of 5 / 10 to VCYT.
What is the valuation status for VCYT stock?
ChartMill assigns a valuation rating of 5 / 10 to VERACYTE INC (VCYT). This can be considered as Fairly Valued.
How profitable is VERACYTE INC (VCYT) stock?
VERACYTE INC (VCYT) has a profitability rating of 6 / 10.
How financially healthy is VERACYTE INC?
The financial health rating of VERACYTE INC (VCYT) is 6 / 10.
What is the expected EPS growth for VERACYTE INC (VCYT) stock?
The Earnings per Share (EPS) of VERACYTE INC (VCYT) is expected to grow by 33.17% in the next year.